NASDAQ:SIBN SiBone (SIBN) Stock Price, News & Analysis $16.39 +0.75 (+4.80%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$16.05 -0.34 (-2.07%) As of 08/22/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About SiBone Stock (NASDAQ:SIBN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SiBone alerts:Sign Up Key Stats Today's Range$15.56▼$16.4850-Day Range$15.20▼$18.8252-Week Range$11.70▼$20.05Volume333,628 shsAverage Volume509,321 shsMarket Capitalization$707.06 millionP/E RatioN/ADividend YieldN/APrice Target$23.67Consensus RatingBuy Company Overview SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. Read More SiBone Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreSIBN MarketRank™: SiBone scored higher than 83% of companies evaluated by MarketBeat, and ranked 180th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSiBone has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSiBone has only been the subject of 1 research reports in the past 90 days.Read more about SiBone's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SiBone are expected to grow in the coming year, from ($0.78) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SiBone is -29.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SiBone is -29.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSiBone has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SiBone's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.52% of the float of SiBone has been sold short.Short Interest Ratio / Days to CoverSiBone has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SiBone has recently decreased by 0.53%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSiBone does not currently pay a dividend.Dividend GrowthSiBone does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-1.44 Percentage of Shares Shorted4.52% of the float of SiBone has been sold short.Short Interest Ratio / Days to CoverSiBone has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SiBone has recently decreased by 0.53%, indicating that investor sentiment is improving. News and Social Media1.1 / 5News Sentiment-0.10 News SentimentSiBone has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for SiBone this week, compared to 3 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, SiBone insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $829,469.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of SiBone is held by insiders.Percentage Held by Institutions98.11% of the stock of SiBone is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about SiBone's insider trading history. Receive SIBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SiBone and its competitors with MarketBeat's FREE daily newsletter. Email Address SIBN Stock News HeadlinesSiBone (NASDAQ:SIBN) SVP Sells $52,065.56 in StockAugust 21 at 8:54 AM | insidertrades.comInsider Selling: SiBone (NASDAQ:SIBN) Director Sells 12,132 Shares of StockAugust 12, 2025 | insidertrades.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 23 at 2:00 AM | The Oxford Club (Ad)SI-Bone Reports Strong Q2 2025 Financial ResultsAugust 5, 2025 | msn.comSI-BONE, Inc. (SIBN) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comSI-BONE, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 4, 2025 | seekingalpha.comSI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 GuidanceAugust 4, 2025 | globenewswire.comSI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025July 29, 2025 | globenewswire.comSee More Headlines SIBN Stock Analysis - Frequently Asked Questions How have SIBN shares performed this year? SiBone's stock was trading at $14.02 on January 1st, 2025. Since then, SIBN shares have increased by 16.9% and is now trading at $16.39. How were SiBone's earnings last quarter? SiBone (NASDAQ:SIBN) released its quarterly earnings data on Monday, August, 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. The firm earned $48.63 million during the quarter, compared to analysts' expectations of $48.12 million. SiBone had a negative trailing twelve-month return on equity of 14.20% and a negative net margin of 12.83%. Read the conference call transcript. Does SiBone have any subsidiaries? The following companies are subsidiaries of SiBone: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD. When did SiBone IPO? SiBone (SIBN) raised $84 million in an initial public offering on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. Who are SiBone's major shareholders? Top institutional investors of SiBone include Brown Advisory Inc. (6.75%), Orbimed Advisors LLC (5.98%), American Century Companies Inc. (5.37%) and Champlain Investment Partners LLC (4.96%). Insiders that own company stock include Laura Francis, Anthony J Recupero, Michael A Pisetsky, Anshul Maheshwari, John Gordon Freund, Timothy E Davis Jr and Mika Nishimura. View institutional ownership trends. How do I buy shares of SiBone? Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SiBone own? Based on aggregate information from My MarketBeat watchlists, some other companies that SiBone investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/04/2025Today8/23/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:SIBN CIK1459839 Webwww.si-bone.com Phone(408) 207-0700FaxN/AEmployees350Year Founded2008Price Target and Rating Average Price Target for SiBone$23.67 High Price Target$25.00 Low Price Target$22.00 Potential Upside/Downside+44.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.91 million Net Margins-12.83% Pretax Margin-12.83% Return on Equity-14.20% Return on Assets-10.38% Debt Debt-to-Equity Ratio0.21 Current Ratio8.38 Quick Ratio7.00 Sales & Book Value Annual Sales$167.18 million Price / Sales4.23 Cash FlowN/A Price / Cash FlowN/A Book Value$3.95 per share Price / Book4.15Miscellaneous Outstanding Shares43,140,000Free Float41,415,000Market Cap$707.06 million OptionableOptionable Beta0.91 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:SIBN) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SiBone Please log in to your account or sign up in order to add this asset to your watchlist. Share SiBone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.